The Kenya government has committed to invest $72 million (Sh7.5 billion) annually on a local plant that will make anti-HIV/Aids drugs.

The partnership with the Global Fund, and the US President’s Emergency Plan for AIDS Relief (PEPFAR) will produce Dolutegravir (DTG) – an anti-Aids drugs with roots in India.

The plan, which was rolled out Wednesday, makes Kenya the first country in the world to introduce the “cheapest” version of the Tivicay ARV brand.
Tivicay is the brand name for DTG’s anti-retroviral ARV, which is manufactured by GlaxoSmithKline through ViiV Healthcare. Tivicay has been available in private hospitals such as the Aga Khan University Hospital at a cost of between $12 and $50.
Prolong the lives
DTG, which will be available for free in public hospitals and select private facilities, is said to have fewer side effects on users and can improve, prolong the lives of tens of thousands of patients, who suffer adverse drug reactions and resistance to other treatments.
“We are starting with 27,000 Kenyans living with HIV who are intolerant to Efavirenz (the first-line HIV drug currently in use), injecting drug users and those in need of third-line treatment,” said the Deputy Director of Medical Services and Head NASCOP, Dr Martin Sirengo.
“DTG generic has no counter-interaction with other drugs like TB medicine and produces fewer side effects.
All patients
more details at http://www.akelicious.com/2017/06/kenya-unveils-cheaper-hivaids-drug.html

good job..wish same could be said of my country

It's admirable not just admirable!